Blue Spark Technologies to Present New Standard of Care for Temperature Monitoring at HIMSS 2023

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, will showcase TempTraq® at the HIMSS Global Health Conference & Exhibition at McCormick Place Convention Center in Chicago April 17-21. The company will present several case studies highlighting how continuous temperature monitoring (CTM) is transforming the standard of care in leading hospitals and clinical trials worldwide.

TempTraq is a comfortable, disposable, wireless patch that measures temperature continuously for up to 72 hours. The FDA and CE Cleared Class II medical device monitors temperature remotely in both inpatient and outpatient settings and alerts clinicians to temperature rise events in real time.

“When common complications like sepsis can become life-threatening in less than an hour, monitoring temperature once every four hours–the current standard of care–is not enough,” said John Gannon, president and CEO, Blue Spark Technologies. “Where time is critical, continuous temperature monitoring with TempTraq helps clinicians take immediate action the moment that temperature spikes.”

At the conference, Blue Spark Technologies will also share several studies comparing continuous temperature monitoring with TempTraq to the standard of care:

One study of patients undergoing chemotherapy or stem cell therapy reported that TempTraq detected 89% of fevers earlier.

In another study, of 23 temperature rise events, 21 were detected a median of 140.1 minutes sooner with TempTraq.

The presentation, “TempTraq, Changing the Standard of Care With Remote Continuous Patient Temperature Monitoring,” will take place Wednesday, April 19 at 12:15–12:35 p.m. Central time at the Innovation Hub, Booths 6009-6034 in Hall B, Level 3, North Building. More information is available here.

Blue Spark Technologies will also be performing live product demonstrations during exhibition hours at Booth 6009-04 in the Innovation Hub. More information is available here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version